You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

6 search results for: mucus

<b>Mucus</b> Plugging Is a Key Component of Remodeling in Asthma, Leading to Fixed Airway Obstruction

Infographic

Mucus Plugging Is a Key Component of Remodeling in Asthma, Leading to Fixed Airway Obstruction

3 min

Pulmonology

Learn about the role of type 2 inflammation in the burden and pathophysiology of mucus plugging in severe asthma

interactivity

Pathways to Disease: Inflammation in COPD

5 min

Pulmonology

Learn about the pathophysiology of COPD and the involvement of chronic inflammation on the airways

expert video

ERS 2024 | Airway Remodeling: A Permanent or Transitory Consequence in Severe Asthma Patients?

78 min

Pulmonology

Professors Celeste Porsbjerg and Klaus Rabe and Dr Mario Castro discuss the pathophysiology of airway remodeling and its impact on patients with severe asthma.

expert video

ERS 2024 | Pathophysiologic Mechanisms of Airway Remodeling in Severe Asthma

14 min

Pulmonology

Professor Celeste Porsbjerg presents the pathophysiology and disease processes involved in airway remodeling in severe asthma.

expert video

ERS 2024 | View From the Clinic: What Are the Clinical Consequences of Airway Remodeling?

29 min

Pulmonology

Professor Klaus Rabe shares a patient case highlighting the burden of disease associated with airway remodeling and discusses practical aspects of identifying and managing airway remodeling in severe asthma patients with Professor Porsbjerg and Dr Castro.

expert video

Airway Remodeling in Type 2 Asthma is Driven by IL-4 and IL-13

24 min

Pulmonology

Dr. Reynold Panettieri discusses how IL-4 and IL-13 drive airway remodeling in type 2 asthma.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: United StatesChange country/region